Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $7.40

Immunic, Inc. (NASDAQ:IMUX) has been assigned an average rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $7.40.

Several equities research analysts recently commented on the stock. Chardan Capital raised shares of Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. HC Wainwright reduced their price objective on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. Roth Mkm started coverage on shares of Immunic in a research note on Friday, November 7th. They set a “buy” rating and a $3.00 target price for the company. Finally, LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research report on Thursday, October 16th.

Immunic Trading Up 0.3%

NASDAQ IMUX opened at $0.66 on Friday. The stock has a market capitalization of $78.87 million, a price-to-earnings ratio of -0.79 and a beta of 1.58. Immunic has a twelve month low of $0.51 and a twelve month high of $1.39. The stock has a 50-day moving average of $0.63 and a 200 day moving average of $0.78.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05. Equities analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunic

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Aberdeen Group plc increased its position in shares of Immunic by 678.1% during the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock worth $5,750,000 after purchasing an additional 7,184,457 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Immunic by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after purchasing an additional 219,957 shares in the last quarter. Focus Partners Wealth boosted its stake in Immunic by 1.5% during the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after purchasing an additional 39,063 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Immunic by 414.5% during the third quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock worth $468,000 after buying an additional 427,361 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Immunic during the third quarter worth $239,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.